SCHEMBL473959

SCHEMBL473959

COc1ccc(Br)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
SLC6A4 P31645 7/20 0.43
HTR1A P08908 2/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
HTR2A P28223 4/20 0.39
KCNH2 Q12809 3/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30193796 1.00 CA12 (0.43) CA12CA1CA2CA7CA9
SCHEMBL7110300 0.98 SLC6A4 (0.42) CA12CA1CA2CA7CA9
SCHEMBL322093 0.84 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL30905970 0.84 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL1134723 0.80 CA1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL30250475 0.80 CA1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL18143914 0.79 AHR (0.59) CYP1A2KDM4EAHR
SCHEMBL18143910 0.79 AHR (0.59) CYP1A2KDM4EAHR
SCHEMBL1145316 0.78 SLC6A4 (0.54) CA12CA1CA2CA7CA9
SCHEMBL29768449 0.78 SLC6A4 (0.54) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637438-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2026-05-26 US disclosed
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2026-02-17 US disclosed
EP-4680612-A1 CHEMICAL COMPOUNDS AN2 Therapeutics, Inc. (US) 2026-01-21 EP disclosed
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-12479834-B2 Phenol compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-11-25 US disclosed
US-12398097-B2 WDR5-MYC inhibitors VANDERBILT UNIVERSITY (US) 2025-08-26 US disclosed
EP-4596537-A1 NOVEL FLUORENE DERIVATIVE COMPOUND AND USE THEREOF JD Bioscience Inc. (KR) 2025-08-06 EP disclosed
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD VIB VZW (BE) 2025-04-10 US disclosed
US-20240391872-A1 PHENOXY-ACETYL-THIOUREIDO-BENZENESULFONAMIDE DERIVATIVES, AND THEIR USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-11-28 US disclosed
WO-2024192309-A1 CHEMICAL COMPOUNDS REACTIVE BIOSCIENCES, INC. (US) 2024-09-19 WO disclosed
WO-2005058906-A1 6-(2-CHLORO-4-ALKOXY-PHENYL)-TRIAZOLOPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND ITS UTILIZATION FOR CONTROLLING FUNGI AND THE AGENTS CONTAINED THEREIN BASF AKTIENGESELLSCHAFT (DE) 2005-06-30 WO disclosed
US-20050101584-A1 Selective estrogen receptor-beta ligands ASTRAZENECA AB (SE) 2005-05-12 US disclosed
WO-2004087709-A1 PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS AND THEIR USES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-10-14 WO disclosed
US-20040204415-A1 Pyrrolo[1,2-B]pyridazine compounds and their uses PFIZER INC 2004-10-14 US disclosed
WO-2004080979-A1 NOVEL 3-(2-AMINO-4-PYRIMIDINYL)-4-HYDROXYPHENYL KETONE DERIVATIVES LG LIFE SCIENCES LTD. (KR) 2004-09-23 WO disclosed
CN-1491225-A Triheterocyclic compounds and drugs containing the same as the active ingredient СҰҩƷ��ҵ��ʽ���� 2004-04-21 CN disclosed
US-20040072833-A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 US disclosed
EP-1354884-A1 TRICYCLIC AND HETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2003-10-22 EP disclosed
EP-1341765-A1 THERAPEUTIC COMPOUNDS AstraZeneca AB (SE) 2003-09-10 EP disclosed
WO-2002046164-A1 THERAPEUTIC COMPOUNDS ASTRAZENECA AB (SE) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 CA12 4779/4885CA1 4878/4885CA2 3687/4885
US-12637438-B2 Protoporphyrinogen oxidase inhibitors PPOX, CYP4X1, CBR3 CA12 2787/4885CA1 1168/4885CA2 288/4885
US-20040204415-A1 Pyrrolo[1,2-B]pyridazine compounds and their uses CRHR1, CRHR2, CRH CA12 3315/4885CA1 2183/4885CA2 2104/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 CA12 3950/4885CA1 2026/4885CA2 3040/4885
US-20240391872-A1 PHENOXY-ACETYL-THIOUREIDO-BENZENESULFONAMIDE DERIVATIVES, AND THEIR USES NAT1, EP300, CCNE1 CA12 2506/4885CA1 3572/4885CA2 3660/4885
US-20050101584-A1 Selective estrogen receptor-beta ligands ESR2, ESRRA, ESRRB CA12 4680/4885CA1 3708/4885CA2 4743/4885
US-12479834-B2 Phenol compound or salt thereof REN, MLX, MYB CA12 2038/4885CA1 1067/4885CA2 612/4885
US-20040072833-A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient CRH, CRHR1, CRHR2 CA12 1821/4885CA1 509/4885CA2 1725/4885
US-12398097-B2 WDR5-MYC inhibitors MYC, WDR5, MYCBP CA12 4808/4885CA1 4853/4885CA2 4637/4885
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 CA12 4874/4885CA1 4878/4885CA2 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.